Topiramate

Generic Name: Topiramate

Brand Names: Eprontia, Qsymia, Qudexy, Topamax, Trokendi

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₂₁NO_₈S

CAS Number: 97240-79-4

Unique Ingredient Identifier: 0H73WJJ391

Background: Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults. Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy in adults.
...

Indication: Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for both adult and pediatric patients above 2 years old 3)Adjunctive therapy for seizures associat...

Associated Conditions: Alcohol Dependency, Epilepsy, Primary Generalized Tonic-Clonic Seizures, Generalized Tonic-Clonic Seizures, Lennox-Gastaut Syndrome, Migraine, Moods Disorders, Partial-Onset Seizures, Seizures, Weight

Associated Therapies: Chronic Weight Management therapy, Weight Reduction

Clinical Trials

Some people don't lose weight with blockbuster obesity drugs

Weight loss pills can aid in weight loss when combined with diet and exercise, helping people lose 3%–9% of body weight in a year. They work by suppressing appetite or blocking fat absorption. Long-term use depends on individual success and side effects, with FDA-approved options for both short-term and long-term use. Other medications like metformin and antidepressants may also aid weight loss off-label. Weight loss surgery is an option with risks, and stopping medication usually leads to weight regain. Weight loss pills should complement, not replace, lifestyle changes.

ajmc.com

a month ago

New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

The Biden administration proposes to revise Medicare and Medicaid regulations to include obesity medications, potentially impacting 3.4 million Medicare and 4 million Medicaid users. This move, pending Trump administration endorsement, aims to reinterpret existing legislation to cover AOMs for obesity treatment, despite anticipated high costs: $25 billion for Medicare and $11 billion for Medicaid.

pharmaceutical-technology.com

a month ago

Eton acquires US rights to neonatal diabetes treatment from AMMTeK

Eton Pharmaceuticals acquired US rights to Amglidia, a neonatal diabetes mellitus treatment from AMMTeK, aligning with its focus on paediatric endocrinology. Amglidia, a liquid product with orphan drug designation, has been used in Europe and will support Eton's NDA submission to the FDA in 2026.

medcitynews.com

2 months ago

Expands Women's Health Options with New Birth Control and Menopause Offerings

GoodRx launched an e-commerce platform with Opill, the first OTC birth control pill in the U.S., offering home delivery. The platform also introduced affordability programs for Pfizer's menopause hormone therapies, amid rising medication costs and the 'Pink Tax' in healthcare.

morningstar.com

2 months ago

VIVUS and UpScriptHealth Announce Launch of ChooseQ.online for Access to Advanced ...

VIVUS and UpScriptHealth launch ChooseQ.online, a telehealth platform for QSYMIA, a leading weight loss medication, enhancing patient access and convenience.

ama-assn.org

3 months ago

Understanding prescription weight loss medication: How can my doctor help me lose weight?

Dr. Janese Laster discusses weight loss drugs, including Ozempic and Wegovy, their mechanisms, costs, insurance coverage, and the importance of lifestyle changes. She explains the differences between oral and injectable medications, their side effects, and the need for physician oversight. Cost varies, with injectables like Wegovy being more expensive, often around $1,500 to $2,000 a month without insurance. Lifestyle changes are crucial for sustained weight loss.